Assessing control bundles for Clostridium difficile: A review and mathematical model

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Yakob, Laith ^a   Riley, Thomas V ^b   Paterson, David L ^a   Marquess, John ^a   Clements, Archie C A ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Epidemiology; Healthcare acquired infection; Infection control bundle; Nosocomial; Stochastic simulation; Transmission model

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; CLOSTRIDIUM DIFFICILE; HOSPITAL INFECTION; HOSPITALIZATION; INFECTION CONTROL; INTESTINE FLORA; LENGTH OF STAY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SANITATION; CLOSTRIDIUM INFECTION; CONTROL STRATEGY; HAND WASHING; HUMAN; INFECTION PREVENTION; INFORMATION RETRIEVAL; MEDICATION COMPLIANCE; MORBIDITY; MOTIVATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRESCRIPTION; REVIEW; SURFACE PROPERTY; THERAPY EFFECT;

CLOSTRIDIUM DIFFICILE;

EID: 84901976695     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.43     Document Type: Article

References (67)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415.
2. Wilcox MH, Smyth ET. Incidence and impact of Clostridium difficile infection in the UK. J Hosp Infect 1998; 39: 181-187.
3. Lo Vecchio A, Zacur G. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9.
4. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficileassociated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-280.
5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142: 624-631.
6. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18: 282-289.
7. He M, Miyajima F, Roberts P et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2012; 45: 109-113.
8. Garcia C, Samalvides F, Vidal M, Gotuzzo E, Dupont HL. Epidemiology of Clostridium difficile-associated diarrhea in a peruvian tertiary care hospital. Am J Trop Med Hyg 2007; 77: 802-805.
9. Dhawan B, Chaudhry R, Sharma N. Incidence of Clostridium difficile infection: a prospective study in an Indian hospital. J Hosp Infect 1999; 43: 275-280.
10. Fernandez-Canigia L, Nazar J, Arce M et al. [Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina.] Rev Argent Microbiol 2001; 33: 101-107. Spanish.
11. Herrera P, Cotera A, Fica A, Galdo T, Alvo M. [High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases.] Rev Med Chil 2003; 131: 397-403. Spanish.
12. Sadeghifard N, Salari MH, Grassemi MR et al. Prevalence of Clostridium difficileassociated diarrhea in hospitalized patients with nosocomial diarrhea. Iranian J Pub Health 2005; 34: 67-72.
13. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficileassociated disease in children. Infect Control Hosp Epidemiol 2007; 28: 1233-1235.
14. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1201-1205.
15. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol 2011; 32: 553-561.
16. Starr JM, Campbell A. Mathematical modelling of Clostridium difficile infection. Clin Microbiol Infect 2001; 7: 432-437.
17. Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ. Spatio-temporal stochastic modelling of Clostridium difficile. J Hosp Infect 2009; 71: 49-56.
18. Rubin MA, Jones M, LeecasterMet al. A Simulation-based assessment of strategies to control Clostridium difficile transmission and infection. PLoS ONE 2013; 8: e80671.
19. Rebmann T, Carrico RM. Preventing Clostridium difficile infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology's elimination guide. Am J Infect Control 2011; 39: 239-242.
20. Weber DJ, Anderson DJ, Sexton DJ, Rutala WA. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control 2013; 41: S105-S110.
21. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial- associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 2008; 46: S19-S31.
22. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficileassociated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-477.
23. Health Protection Agency. Clostridium difficile: findings and recommendations from a review of the epidemiology and a survey of directors of infection prevention and control in England. London: HPA, 2006. Available at http://www.hpa.org.uk/webc/hpawebfile/hpaweb-c/1194947403482 (accessed 29 April 2014).
24. Siegel JD, Rhinehart E, Jackson M, Chiarello L; the Healthcare Infection Control Practices Advisory Committee. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Atlanta, GA: CDC, 2007. Available at http://www.cdc.gov/hicpac/pdf/isolation/ isolation2007.pdf (accessed 29 April 2014).
25. Yakob L, Riley T, Paterson D, Clements A. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis 2013; 13: 376.
26. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
27. Rouphael NG, O'Donnell JA, Bhatnagar J et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obst Gynecol 2008; 198: 635.e1-6.
28. Clements ACA, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010; 10: 395-404.
29. Johnson S, Clabots CR, Linn FV et al. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990; 336: 97-100.
30. Loo VG, Bourgault AM, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703.
31. MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008; 29: 203-211.
32. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007; 44: 664-670.
33. The Organisation for Economic Co-operation and Development. Health at a glance 2011. Paris: OECD, 2011. Available at http://dx.doi.org/10.1787/health- glance-2011-en (accessed 29 April 2014).
34. Rafii F, Sutherland JB, Cerniglia CE. Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag 2008; 4: 1343-1358.
35. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15: 274-280.
36. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
37. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6(S1): S235-S241.
38. Centers for Disease Control and Prevention. Frequently asked questions about Clostridium difficile for healthcare providers 2010. Atlanta, GA: CDC, 2010. Available at: http://www.cdc.gov/hai/organisms/cdiff/cdiff-faqs-hcp.html (accessed 29 April 2014).
39. Khanna S, Pardi D, Aronson S et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107: 89-95.
40. McFarland LV. Update on the changing epidemiology of Clostridium difficileassociated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-48.
41. Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterol 2009; 136: 1899-1912.
42. KeelingM, Rohani P. Modeling infectious diseases in humans and animals. Princeton, NJ: Princeton University Press, 2008.
43. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem 1977; 81: 2340-2361.
44. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-410.
45. Delgado-Rodríguez M, Bueno-CavanillasA, López-GigososRet al. Hospital stay length as an effect modifier of other risk factors for nosocomial infection. Eur J Epidemiol 1990; 6: 34-39.
46. Freeman J, McGowan JE. Risk factors for nosocomial infection. J Infect Dis 1978; 138: 811-819.
47. Goldenberg JZ, Ma SS, Saxton JD et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5: CD006095.
48. Muto CA, Blank MK, Marsh JW et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive ''bundle'' approach. Clin Infect Dis 2007; 45: 1266-1273.
49. Weiss K, Boisvert A, ChagnonMet al. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Infect Control Hosp Epidemiol 2009; 30: 156-162.
50. Abbett SK, Yokoe DS, Lipsitz SR et al. Original article: proposed checklist of hospital interventions to decrease the incidence of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30: 1062-1069.
51. Salgado CD, Mauldin PD, Fogle PJ, Bosso JA. Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. Am J Infect Control 2009; 37: 458-464.
52. Koll BS, Ruiz RE, Calfee DP et al. Prevention of hospital-onset Clostridium difficile infection in the New York Metropolitan Region using a collaborative intervention model. J Health Qual 2014; 36:35-45.
53. Bishop J, Parry MF, Hall T. Decreasing Clostridium difficile infections in surgery: impact of a practice bundle incorporating a resident rounding protocol. Connecticut Med 2013; 77: 69-75.
54. Bauer MP, Notermans DW, van Benthem BH et al. First results of the European Clostridium difficile Infection Survey (ECDIS). 19th European Congress of Clinical Microbiology and Infectious Diseases; 16-19 May 2009; Helsinki, Finland.
55. Pillai A, NelsonR. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; 1: CD004611.
56. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1: 1156-1160.
57. Aldeyab MA, Kearney MP, Scott MG et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67: 2988-2996.
58. Jump RL, Olds DM, Seifi N et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. Infect Control Hosp Epidemiol 2012; 33: 1185-1192.
59. Nathwani D, Sneddon J, Malcolm W et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011; 38: 16-26.
60. Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(S2): S112-S121.
61. Eyre DW, Cule ML, Wilson DJ et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013; 369: 1195-1205.
62. Khanna S, Pardi DS, Aronson SL et al. The epidemiology of community acquired Clostridium difficile infection: a population based study. Am J Gastroenterol 2012; 13: 89-95.
63. Yakob L, Clements AC. A mathematical model of chikungunya dynamics and control: the major epidemic on Re'union Island. PLoS ONE 2013; 8: e57448.
64. Yakob L, Dunning R, Yan G. Indoor residual spray and insecticide-treated bednets for malaria control: theoretical synergisms and antagonisms. J Roy Soc Interface 2011; 8: 799-806.
65. Ferguson N, Keeling MJ, Edmunds WJ et al. Planning for smallpox outbreaks. Nature 1991; 425: 681-685.
66. Meyers LA. Contact network epidemiology: bond percolation applied to infectious disease prediction and control. Bull Am Math Soc 2007; 44: 63-86.
67. Simor AE, Bradley SF, Strausbaugh LJ et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002; 23: 696-703.